TAK-280 for Advanced Cancer
Trial Summary
What is the purpose of this trial?
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
How is the treatment TAK-280 unique for advanced cancer?
TAK-280 is unique because it involves the use of gamma delta T-cells, which are a type of immune cell that can directly attack cancer cells and enhance the body's immune response against tumors. This approach is different from traditional cancer treatments as it leverages the body's own immune system to target and destroy cancer cells.12345
Research Team
Study Director
Principal Investigator
Takeda
Eligibility Criteria
This trial is for adults with advanced or metastatic cancer who haven't responded to standard treatments or can't tolerate them. They should be relatively active (with a good performance status), have measurable disease, and not have had major surgery recently. People with known allergies to TAK-280, autoimmune diseases, recent live vaccines, ongoing infections, low oxygen levels without support, or unresolved wounds are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose-escalation
Participants receive TAK-280 to determine the recommended doses for expansion
Cohort-expansion
Participants receive TAK-280 at determined doses in 28-day cycles until disease progression or withdrawal
Follow-up
Participants are monitored for survival every 12 weeks after the last dose
Treatment Details
Interventions
- TAK-280
Find a Clinic Near You
Who Is Running the Clinical Trial?
Takeda
Lead Sponsor
Dr. Naoyoshi Hirota
Takeda
Chief Medical Officer since 2020
MD from University of Tokyo
Christophe Weber
Takeda
Chief Executive Officer since 2015
PhD in Molecular Biology from Université de Montpellier
Takeda Development Center Americas, Inc.
Industry Sponsor